Zhongshan Laibo Ruichen Biopharmaceutical

Zhongshan Laibo Ruichen Biopharmaceutical (Rabpharma) is a clinical-stage biotechnology company specializing in the development of first-in-class therapeutics for bone and joint diseases. Founded in 2021 and headquartered in Zhongshan, China, the company leverages a proprietary Peptide-Drug Conjugate (PDC) platform to create bone-targeting treatments that recruit mesenchymal stem cells (MSCs) to sites of injury. Its lead candidate, RAB001 (LLP2A-Ale), is a dual-targeting small molecule peptide conjugate currently in Phase 2 clinical trials for non-traumatic osteonecrosis and has received IND clearance for osteoarthritis. The company's R&D is led by a team of experts from UC Davis and is supported by multiple funding rounds to advance its pipeline in osteoporosis and fracture healing.